scholarly journals 2620. Respiratory Syncytial Virus Rapid Antigen Detection Test, Can It Be Trusted?

2019 ◽  
Vol 6 (Supplement_2) ◽  
pp. S912-S912
Author(s):  
Nicole Titze ◽  
Jasjit Singh ◽  
Wendi Gornick
Keyword(s):  
Respiratory Syncytial Virus ◽  
Clinical Decision Making ◽  
Fluorescent Antibody ◽  
Antigen Detection ◽  
Urgent Care ◽  
Viral Fusion ◽  
Rapid Antigen Detection Test ◽  
Viral Fusion Protein ◽  
Test Kit ◽  
Syncytial Virus

Abstract Background Many emergency departments and urgent care settings use the commonly available Respiratory Syncytial Virus Rapid Antigen Detection Test (RSV RADT) to diagnose children with RSV. We noted discordant results between RADT and definitive testing. Our study looked at the positive predictive value (PPV) and the false discovery rate (FDR) of the RSV RADT at our facility. Methods We pro- and retrospectively reviewed all patients with positive RSV RAPD tests from July 1, 2017 through March 31, 2019. The test utilized was the QuickVue® RSV Test Kit (QUIDEL Corp, CA, USA), which detects the viral fusion protein present in RSV. Of the tests performed, we chose patients who had definitive testing with either a direct fluorescent antibody (DFA) or a polymerase chain reaction (PCR). We then calculated the PPV as well as the FDR of the RSV RADT during the total interval period, as well as off-season periods (April 1 through October 31) and in-season periods (November 1 through March 31). Results During the study period there were 1128 RSV RADT tests performed, of which 232 had definitive testing with either DFA or PCR (Figures 1 and 2). We found the overall PPV during the study period was 63.3%. During the off-season 30 positive RSV RADT received definitive testing, of which 6 were positive, which yields a PPV of only 20%. In season, 202 RSV RADT received additional testing with 141 positive for RSV. The PPV was 69.8%. The FDR correlated with 36.7% throughout the entire studied period, 80% during the off-season and 30.2% during in-season. As expected, the PPV was higher during times of higher prevalence (Figure 3). Conclusion Based on our results, utilization of the RSV RADT during time of low prevalence yields a high false detection rate and should therefore be discouraged. The use during times of high prevalence yields only modest results and is unlikely to aid in clinical decision-making. Our results differ from those published by the manufacturer (PPV 84%), and may reflect differences in sample collection in the acute care setting. Disclosures All authors: No reported disclosures.

scholarly journals Detection of Bovine Respiratory Syncytial Virus using a Heterologous Antigen-Capture Enzyme Immunoassay

1989 ◽  
Vol 1 (3) ◽  
pp. 210-214 ◽  
Author(s):  
Fernando A. Osorio ◽  
Gary A. Anderson ◽  
John Sanders ◽  
Dale Grotelueschen
Keyword(s):  
Respiratory Syncytial Virus ◽  
Enzyme Immunoassay ◽  
Solid Phase ◽  
Fluorescent Antibody ◽  
Heterologous Antigen ◽  
Hyperimmune Serum ◽  
Test Kit ◽  
Nasal Swabs ◽  
A Cell ◽  
Syncytial Virus

Based on the marked antigenic similarities that exist between antigens of the human and bovine strains of respiratory syncytial virus (RSV), an enzyme immunoassay (EIA) designed to detect human RSV was used to detect bovine RSV. The commercial test kit (RSV EIA) consists of a solid phase (beads) coated with a capture antiserum prepared against the Long strain of human RSV. The RSV EIA test was compared with the method of inoculation of cell cultures and fluorescent antibody (FA) staining of lung tissue for the detection of bovine RSV. Using a cell culture-propagated stock of strain 375 of bovine RSV, the threshold of sensitivity of the EIA test for the cattle strain of RSV was determined to be ≤ 102,3 CCID50/ml. In addition, RSV EIA detected the bovine RSV in nasal samples obtained from 3 experimentally inoculated cattle. The RSV EIA exhibited a sensitivity of ≥ 80% during the period that shedding of infectious virus took place. All of the bovine RSV FA-positive lung samples (n = 37) were positive by the RSV EIA. Twenty-six of the remaining 214 bovine RSV FA-negative lung samples were positive by the RSV EIA. The RSV EIA was also used to test 137 nasal swabs obtained from cases of bovine respiratory disease. Of these, 38 tested positive by RSV EIA. All samples that tested positive by EIA were confirmed by blocking assays using hyperimmune serum anti-bovine RSV and a pool of monoclonal antibodies specific for that virus.

scholarly journals Rapid antigen detection test for respiratory syncytial virus diagnosis as a diagnostic tool

2017 ◽  
Vol 93 (3) ◽  
pp. 246-252 ◽  
Author(s):  
Flávio da Silva Mesquita ◽  
Danielle Bruna Leal de Oliveira ◽  
Daniela Crema ◽  
Célia Miranda Nunes Pinez ◽  
Thaís Cristina Colmanetti ◽  
...  
Keyword(s):  
Respiratory Syncytial Virus ◽  
Diagnostic Tool ◽  
Antigen Detection ◽  
Virus Diagnosis ◽  
Rapid Antigen Detection Test ◽  
Syncytial Virus

scholarly journals Rapid antigen detection test for respiratory syncytial virus diagnosis as a diagnostic tool

2017 ◽  
Vol 93 (3) ◽  
pp. 246-252
Author(s):  
Flávio da Silva Mesquita ◽  
Danielle Bruna Leal de Oliveira ◽  
Daniela Crema ◽  
Célia Miranda Nunes Pinez ◽  
Thaís Cristina Colmanetti ◽  
...  
Keyword(s):  
Respiratory Syncytial Virus ◽  
Diagnostic Tool ◽  
Antigen Detection ◽  
Virus Diagnosis ◽  
Rapid Antigen Detection Test ◽  
Syncytial Virus

BD Veritor System Respiratory Syncytial Virus Rapid Antigen Detection Test

2015 ◽  
Vol 31 (12) ◽  
pp. 830-834 ◽  
Author(s):  
Richard H. Schwartz ◽  
Rangaraj Selvarangan ◽  
Edward N. Zissman
Keyword(s):  
Respiratory Syncytial Virus ◽  
Antigen Detection ◽  
Rapid Antigen Detection Test ◽  
Syncytial Virus

Antibiotic use in children is not influenced by the result of rapid antigen detection test for the respiratory syncytial virus

2007 ◽  
Vol 39 (3) ◽  
pp. 169-174 ◽  
Author(s):  
Roseline Thibeault ◽  
Rodica Gilca ◽  
Stéphanie Côté ◽  
Gaston De Serres ◽  
Guy Boivin ◽  
...  
Keyword(s):  
Respiratory Syncytial Virus ◽  
Antibiotic Use ◽  
Antigen Detection ◽  
Rapid Antigen Detection Test ◽  
Syncytial Virus

A study of possible biohazards in the fluorescent antibody test using adenovirus, coxsackievirus, herpesvirus, and respiratory syncytial virus as antigens

1976 ◽  
Vol 4 (4) ◽  
pp. 322-325
Author(s):  
D Bardell
Keyword(s):  
Respiratory Syncytial Virus ◽  
Infectious Virus ◽  
Fluorescent Antibody ◽  
Antibody Test ◽  
Adenovirus Type ◽  
Antigenic Determinants ◽  
Syncytial Virus ◽  
Simplex Virus ◽  
Adenovirus Type 5

Infectious adenovirus type 5 and coxsackievirus type B5, both nonlipid-containing viruses, were isolated from cells fixed in acetone at 22 degrees C for 15 min, from acetone used for fixation, from the solution used for washing slides during the fluorescent antibody procedure, and after complete processing of antigen preparations with serial twofold dilutions of human antisera and fluorescein-labeled goat anti-human immunoglobulin G. Lipid-containing herpes simplex virus type 1 and respiratory syncytial virus were inactivated by acetone, and infectious virus could not be recovered at any stage in the fluorescent antibody test. Fixation in acetone at 56 degrees C destroyed the infectivity of adenovirus 5 and coxsackievirus B5 within 30 min, but no adverse effect on the antigenic determinants of either virus occurred until after 60 min, thus demonstrating that these antigens can be utilized without the hazard of infectious virus.

scholarly journals 749. Healthcare Utilization After Hospitalization for Respiratory Syncytial Virus or Unspecified Bronchiolitis in the First Year of Life

2018 ◽  
Vol 5 (suppl_1) ◽  
pp. S268-S269
Author(s):  
Joel Ledbetter ◽  
Lance Brannman ◽  
Sally Wade ◽  
David Diakun ◽  
Tara Gonzales ◽  
...  
Keyword(s):  
Respiratory Syncytial Virus ◽  
Healthcare Utilization ◽  
Healthcare Resource Utilization ◽  
Urgent Care ◽  
First Year ◽  
Chi Squared ◽  
Ed Visits ◽  
Syncytial Virus ◽  
First Year Of Life

Abstract Background Respiratory syncytial virus (RSV) is the leading cause of infant hospitalizations and risk varies by gestational age (GA). Healthcare utilization following early hospitalizations caused by RSV (RSVH) or unspecified bronchiolitis (UBH) is not well understood. This study examined healthcare resource utilization (HRU) across GA categories within 12 months after an initial RSVH or UBH occurring in the first year of life. Methods Infants born July 1, 2009 to June 30, 2015 were identified in the MarketScan Commercial (COM) and Multistate Medicaid (MED) databases and assigned to GA categories using DRG and ICD codes and to an initial hospitalization cohort using inpatient claim diagnosis codes (RSVH, UBH without RSVH, or COMP [a comparator without RSVH or UBH]). Index dates (first admission dates for hospitalized infants) were assigned to COMP infants using times from birth to index dates among RSVH infants. HRU (hospitalizations, outpatient pharmacy fills, and visits for emergency department [ED], urgent care, wellness, other office or outpatient) excluded index hospitalizations and was assessed from 14 days post-index (or discharge if later) through 12 months post-index. Results were propensity score weighted to balance pre-index characteristics (age, sex, region, GA, birth hospitalization characteristics) across cohorts. Proportions were compared with chi-squared tests. Results Among all infants (all GA categories combined), the proportions of RSVH and UBH cohorts with follow-up hospitalizations or ED visits were greater (P < 0.05) than COMP (hospitalizations: COM +5.8%, +9.3%; MED +9.1%, +12.0%; ED visits: COM +15.8%, +16.2%; MED +14.4%, +17.1%). Follow-up hospitalizations in COM and MED and ED visits in COM declined with greater GA (Figures 1 and 2). HRU in other categories (fills, visits) was significantly (P < 0.05) greater among RSVH or UBH infants relative to COMP for nearly all GA categories in both COM and MED. Conclusion Infants hospitalized for RSV or UB in their first year of life had greater use of inpatient and outpatient resources in the 12 months following their initial hospitalizations compared with nonhospitalized infants. Inpatient care during follow-up was greatest among infants born at earlier GA. Funded by AstraZeneca Disclosures J. Ledbetter, AstraZeneca: Speaker’s Bureau, Speaker honorarium. L. Brannman, AstraZeneca: Employee, Salary and Stocks. S. Wade, Wade Outcomes Research and Consulting: Employee, Salary. D. Diakun, Truven Health Analytics, an IBM Company: Employee, Salary. T. Gonzales, AstraZeneca: Employee, Salary and Stocks. A. Kong, Truven Health Analytics, an IBM Company: Employee, Salary.

Sign in / Sign up

Export Citation Format

Share Document